34
Participants
Start Date
March 8, 2016
Primary Completion Date
July 29, 2020
Study Completion Date
July 29, 2020
GLASSIA
Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
Temple University School of Medicine, Philadelphia
Pulmonary Critical Care Associates of Baltimore, Towson
Southeastern Research Center LLC, Winston-Salem
Medical University of South Carolina (MUSC), Charleston
University of Miami, Miami
DBC Research Corp, Pembroke Pines, Tamarac
Cleveland Clinic Florida - Weston, Weston
Dayton Respiratory Research Center, Dayton
LaPorte County Institute for Clinical Research, Inc., Michigan City
University of Chicago Medical Center, Chicago
Hannibal Clinic, Hannibal
University of Texas Health Science Center at Tyler, Tyler
Renovatio Clinical-Respiratory & Sleep Disorders Specialists, The Woodlands
Arizona Board of Regents, University of Arizona, Tucson
UCLA Medical Center, Los Angeles
Cedars Sinai Medical Center, Division of Pulmonary and Critical Care Medicine, Los Angeles
University of California Davis Health System, Sacramento
LHSC - Victoria Hospital, London
Baxalta now part of Shire
INDUSTRY